Belite Bio (BLTE) announced that the FDA has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease based on the previously reported interim data from the ongoing Phase 3 DRAGON trial. There are currently no approved treatments for STGD1.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength
- Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio
- Belite Bio Advances Clinical Trials Amid Financial Challenges
- Belite Bio Advances Tinlarebant Trials with Positive Interim Results
- Belite Bio reports Q1 EPS (27c), consensus (37c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue